Published in PLoS One on October 08, 2012
Safety of Acidform Lubricant in HIV-Uninfected Women | NCT00850837
Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials. Sex Transm Dis (2013) 0.98
Cultivated vaginal microbiomes alter HIV-1 infection and antiretroviral efficacy in colonized epithelial multilayer cultures. PLoS One (2014) 0.83
Use of the dye stain assay and ultraviolet light test for assessing vaginal insertion of placebo-filled applicators before and after sex. Sex Transm Dis (2013) 0.83
Loss of Innate Host Defense Following Unprotected Vaginal Sex. J Infect Dis (2015) 0.78
Poly(ethylene glycol) (PEG)-lactic acid nanocarrier-based degradable hydrogels for restoring the vaginal microenvironment. J Control Release (2014) 0.76
Non-Antiretroviral Microbicides for HIV Prevention. AIDS Rev (2016) 0.75
Vaginal lactic acid elicits an anti-inflammatory response from human cervicovaginal epithelial cells and inhibits production of pro-inflammatory mediators associated with HIV acquisition. Mucosal Immunol (2017) 0.75
Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A (2010) 12.39
Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med (2005) 11.23
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis (2011) 10.96
A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med (1998) 4.35
In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses (2005) 3.89
Targeted PCR for detection of vaginal bacteria associated with bacterial vaginosis. J Clin Microbiol (2007) 3.10
Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis (1998) 2.96
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR. J Clin Microbiol (2009) 2.29
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One (2011) 2.00
Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. JAMA (2002) 1.98
PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS (2007) 1.75
Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. BMC Infect Dis (2008) 1.70
Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr (2001) 1.63
Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis (2001) 1.57
Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception (2007) 1.46
IgG and IgA content of vaginal fluid during the menstrual cycle. J Reprod Med (1989) 1.26
Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis (2009) 1.24
Hormonal contraception and risk of HIV-1 acquisition: results of a 10-year prospective study. AIDS (2004) 1.19
Inhibition of Neisseria gonorrhoeae genital tract infection by leading-candidate topical microbicides in a mouse model. J Infect Dis (2004) 1.18
Assessment of adherence to product dosing in a pilot microbicide study. Sex Transm Dis (2007) 1.07
Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception (2001) 1.06
Validation of a dye stain assay for vaginally inserted hydroxyethylcellulose-filled microbicide applicators. Sex Transm Dis (2011) 1.03
ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations. J Infect Dis (2006) 1.02
Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial. Obstet Gynecol (2007) 1.01
Inhibition of herpes simplex virus infection by lactoferrin is dependent on interference with the virus binding to glycosaminoglycans. Virology (2004) 0.99
Lactobacillus proteins are associated with the bactericidal activity against E. coli of female genital tract secretions. PLoS One (2012) 0.99
Mucosal immunity of the adolescent female genital tract. J Adolesc Health (2003) 0.98
Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis (2012) 0.98
Altered biomarkers of mucosal immunity and reduced vaginal Lactobacillus concentrations in sexually active female adolescents. PLoS One (2012) 0.98
Association of bactericidal activity of genital tract secretions with Escherichia coli colonization in pregnancy. Am J Obstet Gynecol (2012) 0.98
Effects of vaginal intercourse with and without a condom on vaginal flora and vaginal epithelium. J Infect Dis (2001) 0.96
Study of the vaginal tolerance to Acidform, an acid-buffering, bioadhesive gel. Contraception (1999) 0.91
Postcoital testing after the use of a bio-adhesive acid buffering gel (ACIDFORM) and a 2% nonoxynol-9 product. Contraception (2004) 0.85
Results of a safety and feasibility study of the diaphragm used with ACIDFORM Gel or K-Y Jelly. Contraception (2009) 0.79
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol (2013) 5.40
A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (2002) 3.41
2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis (2013) 3.06
Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann Intern Med (2006) 2.85
American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin (2007) 2.81
Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS One (2012) 2.79
Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosis. Appl Environ Microbiol (2008) 2.73
Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PLoS One (2010) 2.62
Seminal plasma reduces the effectiveness of topical polyanionic microbicides. J Infect Dis (2007) 2.57
The human vaginal bacterial biota and bacterial vaginosis. Interdiscip Perspect Infect Dis (2009) 2.56
Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis (2005) 2.55
Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis (2004) 2.31
Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors. Am J Obstet Gynecol (2007) 2.22
Burden of asthma in inner-city elementary schoolchildren: do school-based health centers make a difference? Arch Pediatr Adolesc Med (2003) 2.18
Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 2.15
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev (2008) 2.01
A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS One (2011) 2.00
Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS (2007) 1.95
Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis (2011) 1.94
Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis (2009) 1.81
PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. AIDS (2007) 1.75
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. J Low Genit Tract Dis (2015) 1.73
Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis (2006) 1.72
Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. BMC Infect Dis (2008) 1.70
Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother (2004) 1.69
Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING. Nat Immunol (2012) 1.65
Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol (2006) 1.64
Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women. Gynecol Oncol (2010) 1.64
Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS/NIH/NIAID. Sex Transm Dis (2010) 1.59
Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. Ann Intern Med (2008) 1.59
Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry. J Virol (2004) 1.58
Herpes simplex virus triggers activation of calcium-signaling pathways. J Cell Biol (2003) 1.58
Cultivation of Tropheryma whipplei from cerebrospinal fluid. J Infect Dis (2003) 1.58
PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis (2005) 1.54
Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A (2013) 1.50
A comprehensive murine model to evaluate topical vaginal microbicides: mucosal inflammation and susceptibility to genital herpes as surrogate markers of safety. J Infect Dis (2007) 1.48
Human papillomavirus and cervical cancer. Lancet (2013) 1.48
Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One (2010) 1.46
Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients. Pediatr Transplant (2011) 1.40
Impact of surveillance stool culture guided selection of antibiotics in the management of pediatric small bowel transplant recipients. Pediatr Transplant (2006) 1.39
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis (2010) 1.37
Peripheral blood cytokine profiling during pregnancy and post-partum periods. Am J Reprod Immunol (2010) 1.37
Validation data-based adjustments for outcome misclassification in logistic regression: an illustration. Epidemiology (2011) 1.35
Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother (2012) 1.34
Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol (2008) 1.32
Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother (2005) 1.31
Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol (2015) 1.30
Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis (2005) 1.29
Performance of swabs, lavage, and diluents to quantify biomarkers of female genital tract soluble mucosal mediators. PLoS One (2011) 1.28
Menopause symptoms in HIV-infected and drug-using women. Menopause (2005) 1.27
Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread. J Gen Virol (2002) 1.27
Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J Virol (2008) 1.26
HIV infection, drug use, and onset of natural menopause. Clin Infect Dis (2005) 1.24
Focal adhesion kinase plays a pivotal role in herpes simplex virus entry. J Biol Chem (2005) 1.24
Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol (2009) 1.24
Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.24
Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. Antivir Ther (2009) 1.24
PCR-based diagnosis of human fungal infections. Expert Rev Anti Infect Ther (2009) 1.24
Preclinical evaluation of sodium cellulose sulfate (Ushercell) as a contraceptive antimicrobial agent. J Androl (2002) 1.23
Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS (2007) 1.22
Access to nectin favors herpes simplex virus infection at the apical surface of polarized human epithelial cells. J Virol (2006) 1.22
Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis (2005) 1.22
Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr (2004) 1.21
Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections. J Virol (2007) 1.19
The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr (2003) 1.19
Overcoming the barriers to HPV vaccination in high-risk populations in the US. Gynecol Oncol (2010) 1.19
Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003). Gynecol Oncol (2006) 1.17
Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol Oncol (2007) 1.16
Characterizing the pregnancy immune phenotype: results of the viral immunity and pregnancy (VIP) study. J Clin Immunol (2011) 1.16
Comparison of quantitative real time PCR with Sequencing and ribosomal RNA-FISH for the identification of fungi in formalin fixed, paraffin-embedded tissue specimens. BMC Infect Dis (2011) 1.14
Novel approaches in fighting herpes simplex virus infections. Expert Rev Anti Infect Ther (2009) 1.12
Interaction between lactobacilli, bacterial vaginosis-associated bacteria, and HIV Type 1 RNA and DNA Genital shedding in U.S. and Kenyan women. AIDS Res Hum Retroviruses (2012) 1.11
Therapy of human papillomavirus-related disease. Vaccine (2012) 1.11
Multiple receptor interactions trigger release of membrane and intracellular calcium stores critical for herpes simplex virus entry. Mol Biol Cell (2007) 1.10
Research gaps in defining the biological link between HIV risk and hormonal contraception. Am J Reprod Immunol (2014) 1.08
Calicivirus enteritis in an intestinal transplant recipient. Am J Transplant (2003) 1.08
Risks for acquisition of bacterial vaginosis among women who report sex with women: a cohort study. PLoS One (2010) 1.08
Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety. PLoS One (2011) 1.08
Persulfated molecular umbrellas as anti-HIV and anti-HSV agents. J Am Chem Soc (2004) 1.07
Griffithsin protects mice from genital herpes by preventing cell-to-cell spread. J Virol (2013) 1.07
Assessment of adherence to product dosing in a pilot microbicide study. Sex Transm Dis (2007) 1.07
NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2. Antimicrob Agents Chemother (2003) 1.07
Comparison of oral and vaginal metronidazole for treatment of bacterial vaginosis in pregnancy: impact on fastidious bacteria. BMC Infect Dis (2009) 1.07
Total laparoscopic hysterectomy versus da Vinci robotic hysterectomy: is using the robot beneficial? J Gynecol Oncol (2011) 1.07
More than meets the eye: associations of vaginal bacteria with gram stain morphotypes using molecular phylogenetic analysis. PLoS One (2013) 1.07
Sequencing and analysis of fungal rRNA operons for development of broad-range fungal PCR assays. Appl Environ Microbiol (2009) 1.06
Interlaboratory reproducibility of female genital tract cytokine measurements by Luminex: implications for microbicide safety studies. Cytokine (2011) 1.05
Gender differences in illicit substance use among middle-aged drug users with or at risk for HIV infection. Clin Infect Dis (2006) 1.02
ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations. J Infect Dis (2006) 1.02
Extravaginal reservoirs of vaginal bacteria as risk factors for incident bacterial vaginosis. J Infect Dis (2012) 1.00
Impact of microbicides and sexually transmitted infections on mucosal immunity in the female genital tract. Am J Reprod Immunol (2006) 1.00
Association of HIV viral load with monocyte chemoattractant protein-1 and atherosclerosis burden measured by magnetic resonance imaging. AIDS (2009) 0.99
Lactobacillus proteins are associated with the bactericidal activity against E. coli of female genital tract secretions. PLoS One (2012) 0.99
Altered biomarkers of mucosal immunity and reduced vaginal Lactobacillus concentrations in sexually active female adolescents. PLoS One (2012) 0.98